Nexttrip vs Ping An Biomedical Co.
Ping An Biomedical Co. is the larger business, with $4.7m of revenue in fiscal 2025 against $3.7m for Nexttrip (1.3 times as much). Nexttrip grew faster (641.0% against -61.1%). Ping An Biomedical Co. kept more of each dollar of sales as profit: a net margin of -37.6% against -428.3%. Ping An Biomedical Co. carries less debt relative to equity (22.1% against 63.0%).
| Latest fiscal year | NexttripNTRP, 2026 | Ping An Biomedical Co.PASW, 2025 |
|---|---|---|
| Revenue | $3.7m | $4.7m |
| Revenue growth | 641.0% | -61.1% |
| Net income | −$15.9m | −$1.8m |
| Operating margin | -440.5% | -43.1% |
| Net margin | -428.3% | -37.6% |
| Return on equity | — | -66.7% |
| Free cash flow | −$4.6m | — |
| Cash | $1.7m | $164,697 |
| Total debt | $3.4m | $1.4m |
| Debt to equity | 63.0% | 22.1% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $16.2m | $95.9m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 4 buys, 4 sales | 0 buys, 0 sales |